Head-To-Head Comparison: WuXi PharmaTech (Cayman) (WX) and Intrexon (XON)

WuXi PharmaTech (Cayman) (NYSE: WX) and Intrexon (NYSE:XON) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

Insider & Institutional Ownership

73.3% of Intrexon shares are owned by institutional investors. 55.1% of Intrexon shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.


This table compares WuXi PharmaTech (Cayman) and Intrexon’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
WuXi PharmaTech (Cayman) 7.52% 6.93% 4.67%
Intrexon -66.88% -18.68% -11.34%

Analyst Recommendations

This is a breakdown of current ratings and price targets for WuXi PharmaTech (Cayman) and Intrexon, as reported by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
WuXi PharmaTech (Cayman) 0 0 0 0 N/A
Intrexon 0 1 5 0 2.83

Intrexon has a consensus target price of $38.50, suggesting a potential upside of 205.56%. Given Intrexon’s higher possible upside, analysts clearly believe Intrexon is more favorable than WuXi PharmaTech (Cayman).

Earnings and Valuation

This table compares WuXi PharmaTech (Cayman) and Intrexon’s top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
WuXi PharmaTech (Cayman) N/A N/A N/A $1.18 38.91
Intrexon $190.93 million 8.42 -$186.61 million ($1.12) -11.25

WuXi PharmaTech (Cayman) has higher earnings, but lower revenue than Intrexon. Intrexon is trading at a lower price-to-earnings ratio than WuXi PharmaTech (Cayman), indicating that it is currently the more affordable of the two stocks.

About WuXi PharmaTech (Cayman)

WuXi PharmaTech (Cayman) Inc. is a pharmaceutical, biotechnology and medical device research and development (R&D) services company, with operations in China and the United States. The Company provides a portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process to its customers. It conducts its operations in two segments: Laboratory services and Manufacturing services. The Company offers Laboratory services for pharmaceutical, biotechnology and medical device companies. It offers Manufacturing services, which include the development of manufacturing processes and the production of advanced intermediates and active pharmaceutical ingredients (APIs) for use by pharmaceutical companies in preclinical and clinical trials of small-molecule products and in commercial products, as well as the production of biologic products.

About Intrexon

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components. The Company’s synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells and optimize for desired results at an industrial scale. The Company’s technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing (LEAP), and ActoBiotics platform.

Receive News & Ratings for WuXi PharmaTech (Cayman) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for WuXi PharmaTech (Cayman) and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply